Welcome to the Hope Bio Blog

By Jan Shultis, Ph.D. Last year, Hope Biosciences was privileged to announce a four-year, nearly $5 million clinical trial grant awarded by the Department of Defense’s Office of Congressionally Directed Medical Research Programs (CDMRP) to evaluate if intravenously infused Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) reduce chronic neuroinflammatory response to severe traumatic brain injury (TBI). Hope Biosciences with the team at UTHealt

By Jan Shultis, Ph.D. Baseball is known as “America’s Game,” but other athletic events vie for top place in popular imagination of American culture, including American football, Ultimate Fighting Championship (UFC), and entertainment-based enterprises like World Wrestling Entertainment (WWE). From a healthcare perspective, these pursuits have things in common – like people getting hurt, a lot, especially through concussive trauma and other head, skeletal, and nervous system i

By Jan Shultis, Ph.D. In 2023, Texas-based biopharmaceutical company Hope Biosciences cultured approximately 170 billion adult stem cells for use in dozens of disease and injury conditions, including in 18 FDA-authorized research protocols. It was a year that saw a new volume of peer-reviewed publications, conference presentations, and community engagements. Also in 2023, Hope Biosciences increasingly became a household name in skincare, with a partner’s very public launch of